

BBANYS  ANNUAL MEETING



*Race to the Rescue*

at The Gideon Putnam Resort in  
SARATOGA SPRINGS

MAY 16-17 2019

**BBANYS 2019 Annual Meeting**  
**Race to the Rescue**  
**May 16 - 17, 2019**

Our 2019 BBANYS Annual Meeting has Scientific and Technical tracks on both Thursday and Friday.

Below are descriptions of the presentations, including learning objectives.

**Thursday, May 16, 2019**

Gideon Putnam Resort, Saratoga Springs, NY

**Keynote Speaker**

8:00 - 9:00 a.m.

**Keynote: AABB Inter-Organizational Task Force on Domestic Disasters and Acts of Terrorism**

**Speaker:** Dennis M. Todd, PhD

**Description:** This presentation will describe the workings of a task force charged with providing support to blood centers nationwide in times of disasters.

**Objectives:** 1. Describe the AABB Taskforce objectives. 2. Provide examples of previous activities.  
3. Suggest how hospitals can support taskforce efforts.

## Scientific and Clinical Track

9:00 – 10:00 a.m.

### **Massive Transfusion Protocols: 2019 and Beyond**

**Speaker:** Eric Gehrie, MD

**Description:** A presentation on current massive transfusion protocols including a discussion of ratio-driven, component-based protocols and the use of whole blood in massive transfusions.

**Objectives:** 1. Explain the rationale for ratio-driven, component based massive transfusion. 2. Discuss the basis for the use of whole blood for trauma resuscitation. 3. Explain the implications of leukoreduction on the hemostatic efficacy of whole blood.

10:30 - 11:30 a.m.

### **Massive Transfusion Practice in the Non-Trauma Setting**

**Speaker:** Robert A. DeSimone, MD

**Description:** This presentation will review the current literature and practice of using massive transfusion protocols (MTPs) in the non-trauma setting. Non-trauma hemorrhage patients are a heterogeneous population and have more co-morbidities and different sources of bleeding relative to trauma patients. We will investigate if resuscitation practices such as specified blood product ratios used in the trauma setting are applicable to non-trauma hemorrhage.

**Objectives:** 1. Review the current literature on non-trauma massive transfusion protocol (MTP) practice, including indications for MTP, blood product ratios, blood product utilization, and patient outcomes. 2. Define future areas of collaborative research in the setting of non-trauma hemorrhage.

11:30 a.m. - 12:30 p.m.

### **Emergency Planning for NYBC: Ensuring a Robust Blood Supply**

**Speaker:** Donna Strauss, MS

**Description:** In this session you will hear how New York Blood Center plans for and deals with emergencies including Hurricane Sandy, 9/11 and how they ensure blood is available when needed.

**Objectives:** 1. Explain how different emergencies require different responses. 2. Explain all of the processes that are performed to ensure an adequate blood supply is available. 3. Describe the challenges of inventory management for different products.

2:00 - 3:00 p.m.

### **Platelet Management Strategies During Disaster and Severe Shortage**

**Speaker:** Teresa Boyd, MD

**Description:** Platelet components are vital for the management and survival for trauma, cardiothoracic surgery, and cancer. They are also the most tenuous of the blood components with the shortest shelf life. During times of shortage critical decisions must be made in relation to collection strategies, inventory management, and transfusion that pose questions of great ethical significance.

**Objectives:** 1. Inform participants about challenges of platelet collection during disaster. 2. Provide insight into management strategies at collection facilities and hospital transfusion services. 3. Discuss ethical dilemmas in clinical decision making for transfusion of platelets and mitigating strategies.

3:00 - 4:00 p.m.

### **Anticoagulants & Their Reversal: The Lab Medicine & Blood Bank Perspective**

**Speaker:** Christopher A. Tormey, MD

**Description:** With the evolution of numerous novel anticoagulants, it is not uncommon for patients to develop complex bleeding while on these drugs. However, the lab monitoring and reversal of such agents is challenging and lacks a "one size fits all" approach. In this session we will review the mechanism of action of the various forms of anticoagulation, discuss how drugs can be monitored from the coagulation laboratory, and finally highlight evidence-based strategies for their reversal.

**Objectives:** 1. Review the mechanisms of traditional as well as more novel forms of anticoagulation.

2. Discuss how such anticoagulants can be monitored from the coagulation laboratory perspective.
3. Describe blood product as well as pharmaceutical approaches to reversing anticoagulants.

4:30 - 5:30 p.m.

### **Oral Abstract Presentations**

## **Technical Track**

9:00 – 10:00 a.m., 10:30 - 11:30 a.m.

### **Antibody Identification from Simple to Complex**

**Speaker:** JoAnn Christensen, MS, MT(ASCP)SBB<sup>CM</sup>

**Description:** Simple to complex methods of antibody identification will be discussed in a case review format. A variety of patient test cases will be presented with in depth analysis of panel cell reactivity. Methods used to resolve patient test cases will be reviewed. Audience participation will be encouraged. Participants may be asked to determine next steps in patient testing, select panel cells to conclude testing and estimate the likelihood of obtaining compatible red blood cells for transfusion.

**Objectives:** 1. Describe exclusionary criteria used in antibody identification. 2. Evaluate red blood cell panel reactivity and determine next step testing needs to conclude antibody identification. 3. Determine the likelihood of finding compatible red blood cells for transfusion.

11:30 a.m. - 12:30 p.m.

### **American Rare Donor Program (ARDP)**

**Speaker:** Joan L. Maurer, BS, SBB(ASCP)

**Description:** This session will discuss the use of the American Rare Donor Program to obtain rare red blood cells.

**Objectives:** 1. Describe the ARDP: What is the ARDP? What is considered a rare blood request? 2. Define the challenges in meeting the red cell transfusion needs of patients who need rare blood. 3. Describe the role of molecular testing in identifying rare donors and meeting the needs of patients who need rare blood. 4. Discuss how the ARDP can impact patients in the USA and abroad.

CME Credits: 1.0

2:00 - 4:00 p.m.

### **What Now? Case Studies and Management of Rare Antibodies**

**Speaker:** Sabino R. Curcio, MS, MLS(ASCP)

**Description:** Case studies involving rare and uncommon antibodies will be presented. The management of patient care and collaboration with a local blood center to obtain blood products required will be thoroughly discussed.

**Objectives:** 1. Review rare antibody identification case studies. 2. Describe the planning required to obtain blood for possible transfusion with the blood center. 3. Describe the collaboration between the blood bank and patient care teams to ensure availability of blood products.

4:30 - 5:30 p.m.

### **Oral Abstract Presentations**

**Friday, May 17, 2019**  
Gideon Putnam Resort, Saratoga Springs, NY

### **Scientific and Clinical Track**

8:00 – 9:00 a.m.

#### **FDA Emergency Preparedness and Response**

**Speaker:** Emily Storch, MD

**Description:** This presentation will provide information on FDA's system for emergency preparation and disaster response, the use of acceptable and available products, and new initiatives for rapid availability of emergently needed products.

**Objectives:** 1. Describe FDA's emergency response plan. 2. List programs in place and FDA options for providing emergent access to medical products. 3. Provide examples of FDA inter-agency collaboration in disaster preparedness and response.

9:00 – 10:00 a.m.

#### **NYSDOH is Knocking at Your Door – Are You Ready?**

**Speaker:** Kathleen Wagner, MT(ASCP)

**Description:** This presentation will help you understand the regulatory requirements to ensure your laboratory is in compliance with current NYSDOH regulations and who to contact if you have questions on how to obtain compliance.

**Objectives:** 1. Discuss the regulatory requirements. 2. Recognize what is needed to bring your laboratory into compliance with the Department's regulatory requirements. 3. List who to contact if you have a question about the regulatory requirements and how to obtain compliance.

11:00 a.m. - 12:00 p.m.

#### **Planes, Trains and Automobiles: Transfusions That Occur Outside the Hospital Setting**

**Speaker:** Cheryl Goss, MD

**Description:** Changes in healthcare practice are increasing the need for non-traditional transfusion settings. This presentation covers current regulations and challenges associated with non-hospital based transfusions.

**Objectives:** 1. Describe the applicable regulations associated with non-hospital transfusions. 2. Describe complications associated with non-hospital based transfusions.

12:00 - 1:00 p.m.

#### **Massive Transfusion Protocol – The Dark Side**

**Speaker:** Lawrence Benton Fialkow, DO

**Description:** MTPs are effective means of treating trauma patients. However, we need to be aware of the adverse complications that can occur with the use of these protocols.

**Objectives:** 1. Explain the potential adverse effects that can occur in patients undergoing MTPs. 2. Recognize and describe treatment and/or avoidance of MTP complications.

## Technical Track

8:00 – 10:00 a.m., 11:00 a.m. – 1:00 p.m.

### **Antibody Screening is Only the Beginning...**

**Speakers:** Christine Lomas-Francis, MSc, FIBMS, and Kim Wilson-Sandberg, FIBMS, BSc

**Description:** Fascinating case studies will be presented to expand the understanding of serological and DNA methods that aid complex antibody resolution and approaches to provide the best RBC product for transfusion. Cases will demonstrate the benefit of close collaboration between the hospital transfusion service and the immunohematology reference laboratory.

**Objectives:** 1. Review serological and molecular methods that can aid complex antibody identification.  
2. Describe close collaboration between transfusion service and immunohematology reference laboratories to support patients with challenging antibody profiles.